Nevakar Announces New Collaborative Research Agreement with Princeton University

Friday, September 29, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

BRIDGEWATER, N.J., Sept. 29, 2017 /PRNewswire/ -- Nevakar LLC, a privately-held specialty pharmaceutical company developing

innovative therapies within the injectable and ophthalmic space, today announced a collaborative research agreement with Princeton University, using Princeton's proprietary nanoparticle platform
to develop unique formulations of oncology and anti-infective drug molecules. 

"This research agreement with Princeton University furthers our efforts to develop enhanced and innovative products that leverage novel scientific and technology platforms," said Navneet Puri, Ph.D., founder and chief executive officer of Nevakar.

About Princeton UniversityPrinceton is a not-for-profit institution of higher education dedicated to advancing learning through scholarship, research, and teaching of unsurpassed quality, with an emphasis on undergraduate, and doctoral education that is distinctive among the world's great universities, and with a persuasive commitment to serve the nation and the world. 

About NevakarNevakar is a specialty pharmaceutical company focused on therapies within the injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently FDA-approved molecules, through intensive R&D and clinical efforts. Nevakar has a comprehensive infrastructure for product development at its New Jersey facilities.  More information about Nevakar can be found at www.nevakar.com.

CONTACTSAt Nevakar:Marshall Woodworth Chief Financial Officer(908) [email protected]

At Rx Communications Group:Paula Schwartz(917) [email protected]

 

View original content:http://www.prnewswire.com/news-releases/nevakar-announces-new-collaborative-research-agreement-with-princeton-university-300528170.html

SOURCE Nevakar LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store